GSA Capital Partners LLP Trims Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

GSA Capital Partners LLP cut its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 22.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 41,029 shares of the biopharmaceutical company's stock after selling 12,200 shares during the period. GSA Capital Partners LLP owned about 0.07% of Agios Pharmaceuticals worth $1,202,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in AGIO. Vanguard Group Inc. grew its holdings in Agios Pharmaceuticals by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock valued at $185,045,000 after purchasing an additional 85,339 shares during the last quarter. Jefferies Financial Group Inc. purchased a new stake in Agios Pharmaceuticals during the fourth quarter worth approximately $49,290,000. Frazier Life Sciences Management L.P. lifted its position in Agios Pharmaceuticals by 2.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 1,069,754 shares of the biopharmaceutical company's stock worth $35,152,000 after acquiring an additional 25,600 shares in the last quarter. Deutsche Bank AG lifted its stake in shares of Agios Pharmaceuticals by 39.7% in the fourth quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company's stock worth $30,732,000 after acquiring an additional 265,637 shares in the last quarter. Finally, ArrowMark Colorado Holdings LLC increased its position in shares of Agios Pharmaceuticals by 3.9% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 917,420 shares of the biopharmaceutical company's stock worth $30,146,000 after purchasing an additional 34,689 shares during the last quarter.

Insiders Place Their Bets

In other news, CEO Brian Goff sold 18,700 shares of the business's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total transaction of $627,198.00. Following the transaction, the chief executive officer directly owned 105,401 shares of the company's stock, valued at approximately $3,535,149.54. The trade was a 15.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Tsveta Milanova sold 2,770 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total transaction of $92,905.80. Following the completion of the transaction, the insider directly owned 26,122 shares in the company, valued at approximately $876,131.88. The trade was a 9.59% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 46,363 shares of company stock valued at $1,619,654 over the last three months. Corporate insiders own 4.93% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on AGIO. Bank of America cut their price target on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. Wall Street Zen lowered shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. Finally, Scotiabank cut their price objective on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a report on Monday, July 28th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $56.33.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO traded down $5.56 on Monday, reaching $29.45. The stock had a trading volume of 2,140,289 shares, compared to its average volume of 693,882. The firm has a fifty day moving average of $35.69 and a two-hundred day moving average of $32.57. The company has a market cap of $1.71 billion, a P/E ratio of 2.67 and a beta of 0.80. Agios Pharmaceuticals, Inc. has a 1-year low of $23.42 and a 1-year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.19). The firm had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.46 million. Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%. Research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.